cis-pyrrolidine-2,5-dicarbonitrile | 1039741-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: cis-pyrrolidine-2,5-dicarbonitrile
• 英文别名: (2S,5R)-pyrrolidine-2,5-dicarbonitrile
• CAS: 1039741-48-4
• 化学式: C₆H₇N₃
• 分子量: 121.142
• InChiKey: SPUVQIMVLPIAFV-OLQVQODUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  59.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  cis-pyrrolidine-2,5-dicarbonitrile 在 盐酸 、 lithium aluminium tetrahydride 、 氯化亚砜 、 氯仿 、 硫酸 、 水 、 sodium cyanoborohydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 88.0h， 生成 [(2R,5S)-5-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1-methylpyrrolidin-2-yl]methanol
  参考文献：
  名称：

  外消旋和内消旋吡咯烷-2,5-二羧酸酰胺的对映选择性生物转化及其在有机合成中的应用

  摘要：

  在本文中，我们报道了酰胺酶催化的吡咯烷-2,5-二甲酰胺的水解及其在有机合成中的应用。在红球菌红球菌AJ270的催化下，将含有酰胺全酶的微生物全细胞催化剂，外消旋的反式-吡咯烷-2,5-甲酰胺动力学拆分为（2 S，5 S）-吡咯烷-2,5-二甲酰胺和（2 R，5 R）-5-氨基甲酰基吡咯烷-2-羧酸的高收率和优异的对映选择性。生物催化脱对称的内消旋顺式-吡咯烷二甲酰胺提供对映体纯的（2 R，5 S）-5-氨基甲酰基吡咯烷-2-羧酸的产率几乎是定量的。在动力学拆分和去对称化方面，酰胺酶始终表现出优异的2 R-对映选择性，尽管其催化效率受吡咯烷环氮原子上取代基的空间效应影响很大。通过可扩展的制备（2 R，5 R）-和（2 R，5 S）-5-氨基甲酰基吡咯烷-2-羧酸及其转化为氮杂核苷类似物和类似药物的吡咯啉的方法，证明了生物转化的合成潜力。diazepin-11（5 H）-one化合物。

  DOI：

  10.1021/jo300412j
• 作为产物：
  描述：

  cis-1-(diphenylmethyl)pyrrolidine-2,5-dicarbonitrile 在 三乙基硅烷 、 三氟乙酸 作用下， 以 苯甲醚 为溶剂， 反应 1.0h， 生成 cis-pyrrolidine-2,5-dicarbonitrile
  参考文献：
  名称：

  EP2123651

  摘要：

  公开号：

文献信息

• CONDENSED PYRIDINE COMPOUND
  申请人：Shirakami Shohei

  公开号：US20100105661A1

  公开（公告）日：2010-04-29

  The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

  本发明提供了一种具有出色JAK3抑制活性的化合物，可作为治疗和/或预防各种免疫疾病，包括自身免疫性疾病、炎症性疾病和过敏性疾病的药剂的有效成分。通过对新型紧缩杂环衍生物的研究，发明人已经验证，紧缩吡啶化合物具有出色的JAK3抑制活性，从而完成了本发明。更具体地说，已经验证，由于本发明的化合物具有对JAK3的抑制活性，因此该化合物可用作治疗或预防由不良细胞因子信号转导引起的疾病（例如，在活体器官/组织移植期间的排斥反应、自身免疫性疾病、哮喘、特应性皮炎、风湿病、牛皮癣和动脉粥样硬化疾病），或由异常细胞因子信号转导引起的疾病（例如癌症和白血病）的有效成分。
• METHODS FOR IDENTIFYING SUBJECTS WITH AN INCREASED LIKELIHOOD OF RESPONDING TO DPP-IV INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2281069A2

  公开（公告）日：2011-02-09
• Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors
  申请人：Koustubh Ranade

  公开号：US20110020797A1

  公开（公告）日：2011-01-27

  The invention provides novel in vitro diagnostic methods for identifying patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides, which comprise at least one polymorphic locus per fragment, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis.
• Methods for Identifying Subjects With an Increased Likelihood of Responding to DPP-IV Inhibitors
  申请人：Emison Eileen

  公开号：US20110152340A1

  公开（公告）日：2011-06-23

  The invention provides novel in vitro diagnostic methods for identifying subjects or patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments which comprise at least one polymorphic locus, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the invention are useful in phenotype correlations, medicine, and genetic analysis.
• [EN] METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF RESPONDING TO DPP-IV INHIBITORS<br/>[FR] PROCÉDÉS POUR L'IDENTIFICATION DE PATIENTS AYANT UNE FORTE PROBABILITÉ DE RÉAGIR AUX INHIBITEURS DE DPP-IV
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2008098256A1

  公开（公告）日：2008-08-14

  [EN] The invention provides novel in vitro diagnostic methods for identifying patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides, which comprise at least one polymorphic locus per fragment, are also provided. Allele- specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis.
  [FR] L'invention concerne de nouveaux procédés de diagnostic in vitro pour l'identification de patients qui peuvent présenter une forte probabilité de réaction à une thérapie d'inhibiteurs de DPP-IV. L'invention propose également de nouveaux polynucléotides associés à la réaction accrue d'un patient à l'inhibition de DPP-IV. Des fragments de polynucléotides correspondant aux régions génomiques et/ou de codage de ces polynucléotides, qui comprennent au moins un locus polymorphe par fragment, sont également proposés. Des amorces et des sondes qui hybrident au niveau de ces régions polymorphes et/ou qui comprennent au moins un locus polymorphe sont également proposées. Les polynucléotides, les amorces et les sondes de la présente invention sont utiles dans les corrélations du phénotype, la médecine et l'analyse génétique.